Clinical trial finds no benefit from aspirin in preventing colorectal cancer recurrence

by

A new international clinical trial led by the National Cancer Center Singapore is reporting that three years of aspirin following standard adjuvant therapy for high-risk Dukes’ B and C colorectal cancer did not yield a significant advantage in preventing disease recurrence.

Leave A Comment

Your email address will not be published. Required fields are marked *